Can a cold virus drug ease COPD Flare-Ups? new trial results are in
NCT ID NCT06149494
First seen Oct 31, 2025 · Last updated Jun 15, 2026 · Updated 37 times
Summary
This study tested whether vapendavir, an experimental antiviral drug, could reduce lower respiratory symptoms (like cough, wheezing, and shortness of breath) in 52 adults with COPD who were deliberately exposed to a common cold virus (rhinovirus). The goal was to see if the drug could prevent or lessen the severity of COPD flare-ups triggered by the virus. The trial has been completed, and the results will show how well vapendavir worked compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU)
London, W2 1NY, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.